Patient Rating:

4.9 out of 5

159 Patient Ratings
85 Patient Comments

Wallace L. Akerley, M.D.

Patient Rating:

4.9 out of 5

159 Patient Ratings
85 Patient Comments

Clinical Details

Phone Number Clinical Office Address
(801) 213-4266 Huntsman Cancer Hospital
Clinic 1A, Thoracic
1950 Circle of Hope
Salt Lake City, UT 84112
Map

Bio

Wallace Akerley, MD is a medical oncologist with greater than 20 years experience as a principal investigator on numerous clinical research trials who actively cares for lung cancer and melanoma patients.

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor
Academic Divisions Oncology
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)
National Board of Medical Examiners
Cancer Center Programs Experimental Therapeutics

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending care provider
4.9
My confidence in care provider
4.9
Time care provider spent with me
4.9
Care provider spoke using clear language
4.9
Care provider's effort to include me in decisions
4.9
Care provider's concern for questions & worries
4.9
Care provider's explanation of condition/problem
4.9
Wait time at clinic
3.8
Care provider's friendliness and courtesy
4.9

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

June 27, 2015

very good team

June 12, 2015

I know it was the second time to hear the information, but I came away with a much better understanding.

June 10, 2015

If I didn't have a "sick" partner here in Las Vegas, I certainly would have treated at the Huntsman Center.

May 22, 2015

dr ackerley is great and i really appreciate his advice.

May 19, 2015

good

May 11, 2015

I think based on my meeting with the doctor that he has preconceived opion about me. It was negative regarding any assistance for my care. Therefore, he did not examine me. Based on his examination and meeting with me, I did not need to come to Utah. The rest of the staff was very interactive, listened and supportive. Perhaps in future, he may want to inform the referring doctor that he would not be of any help. It would save the patient time, energy, money to make the trip.

May 04, 2015

I kept him too long as I was trying to process what he was telling me, so that probably made him late for other appointments. He was so helpful and kind!

April 08, 2015

I feel I have the best team I could ask for supporting me through this illness

March 27, 2015

The Dr. spent good time with us, the NP is great. the PA was not good.

March 09, 2015

Very little information on effects of Radiation after completion of last dose. No interview with anyone. This is critical in my opinion. I had no idea how fatiqued I would feel.

March 09, 2015

Dr Akerley and his team helped me become at peace during this time while I LIVE with my cancer. I felt encouragement to make the best of each and every day. The LCSW is excellent at conveying compassion and understanding.

February 23, 2015

Dr. Akerley didn't have all the information he should have been given so instructions or decisions will wait for a phone call from him.

February 17, 2015

I would recommend Dr. Ackerley to others.

February 14, 2015

I couldn't wish for a better experience

February 07, 2015

great

January 24, 2015

A1 clinic's staff is outstanding

January 18, 2015

W are so impressed with Dr Akerley. He is obviousl knowledgeable, but he took the time needed with us, and made us feel like we were the most important thing at that time. His explanations were acccurate, and laced with compassiion, hope and mercy.

January 13, 2015

completely reassured by my visits with Dr. Wally Akerley that issues have been attended to and that I am doing the best I can with my disease state.

December 22, 2014

Julie and Dr. Akerley are a great team and I feel very fortunate to be in their care.

December 18, 2014

There is NO bad bad experience with this oncology team. These people are are awsome, one could not wish for more or better, they make a really nasty disease much easier to deal with. I thank all three of them from the bottom of my heart

December 16, 2014

Dr. Ackerley is very caring and kind as well as professional. I could not have asked for better care.

November 24, 2014

Outstanding service provided by each of the care providers. I felt as if I was getting special care from everyone involved.

October 08, 2014

I am always treated very well when I have to go.

October 05, 2014

I would highly recommend Dr. Akerley to others, and have done so.

September 14, 2014

Excellent

September 08, 2014

Time was personally given to me, to help me fully understand my situation and future medical needs.

July 20, 2014

I saw Dr. Akerley and Terry Van Duren during this visit. They are always thorough, friendly and answer all my questions or get the answers if they are not available. I give them our highest praise as well.

July 17, 2014

The entire care provider staff is very thoughtful

July 09, 2014

We were impressed by Dr Akerley's compassion and concern for me as a patient. He has a very healing professional style.

July 04, 2014

I fill I was, and am, in the best of hands

June 16, 2014

Dr Ackerley is the most competent Dr. I have ever had. His concerns for me as well as my family are amazing. I have so much confidence in him and his staff. He is a pleasure to work with

June 15, 2014

Appreciate Dr. Ackerly's time he spends with us and his willingness to debate treatment options

June 10, 2014

I would recommend Huntsman to everyone I talk to!!!!! Awesome place and staff!!!!!

May 16, 2014

Julie spent a lot of time answering our questions with regards to medication side effects and the cancer itself. She also provided additional help in ensuring my fathers overall help. I am amazed at the teams ability to assess and treat the overall wellness especially the emotional and mental aspects. Dr Akerley and team are amazing every time we visit.

April 26, 2014

The doctor was awesome!, likewise the assistants.

April 16, 2014

Dr. Akerley, Terry and Julie are the best. As was Dr. Sharma and Cynthia when I was seeing them a couple of years ago during a study.

March 28, 2014

We enjoyed the time Julie, NP spent with us. She was friendly, informative, filled with information. Dr. Akerley was just as friendly, informative, and filled with information. It was a lot of information to grasp. Maybe a break sometime along the way would have been a good idea.

March 06, 2014

We appreciate Dr. Akerley, Julie, Terry for the one on one care they give to me the patient, and to my husband. They are very patient with my questions and going over any treatment plan.

March 03, 2014

My dad was treated with such respect, kindness & compassion

February 13, 2014

Amazing! And the time that Dr. Akerley spent with us was amazing!

February 01, 2014

As with the assistant, the doctor could have abbreviated the explanations to fit the ability of the patient to understand. The doctor gave generously of his time, and the last few minutes helped more than everything prior as he responded to our questions.

January 07, 2014

I put my entire care in their hands with confidence

December 06, 2013

Dr Ackerly was extremely personable, professional, yet able to relate to me on a human level. I was able to follow him, without feeling inept. I would recommend HCI again. I am completely confident in their recommendations and would come to HCI anytime I had a need.

November 25, 2013

I would highly recommend Dr. Akerley to anyone, as he is a very caring, thorough, and knowledgeable doctor and has been very helpful to me.

September 23, 2013

Dr. Akerley is seriously a great person to have as a doctor (along with Julie and his staff). He shows the utmost respect and concern for me and my treatment. I highly recommend him. He always shows concern for me and the pains or side effects that I might have. He never brushes your concerns off and understands my needs and addresses them properly.

September 04, 2013

Dr. Akerley was unfamiliar with my condition initially. My husband, who is a pulmonary, critical care physician, explained it and clarified it for him. This was due to the inadequate records provided to him. I was told that all the records were received prior to the appointment but they were not. He did not have the final pathology report and other records which would have helped him better know my case. I know that he later reviewed them and spoke with my oncologist here in Medford, OR. I liked him very much and he was very helpful. I feel like I am getting the best option of treatment with his input.

August 21, 2013

The doctors and staff have been supper to me. I don't know what could be changed other than not being sick.

August 19, 2013

Love Dr Akerley and have complete confidence in his recommendations

August 07, 2013

I would recommend Huntsman to everyone one I have contact with, that need cancer care!

August 05, 2013

Again, just an unbelievable experience. They did not make me feel less of a person due to this cancer. I heard a more complete explanation of what I have been going thru these past three years and what to expect in the future. Using the diagram helped immensley along with past/current scans and what they showed.

July 16, 2013

You could not ask for better care.

July 11, 2013

so much concern and understanding

June 10, 2013

good

May 28, 2013

Dr. Akerley is an exemplary physician with a wonderful sense of humor and understanding demeanor. He often has to put up with some teasing from me and sometimes irreverent humor of both myself and my husband.

April 19, 2013

Everything was good

March 25, 2013

good

February 25, 2013

excellent

February 21, 2013

My experiance has been nothing but positive.

February 18, 2013

I already have reccommended U of U hosp. and Huntsman. They saved my life. What fabulous care!!

February 05, 2013

Overall I felt they had my concerns in mind.

February 04, 2013

We were late going into the exam room, but it was our fault as we were waiting for other family members to get to the clinic. Still, Dr. Akerley and Terry spent plenty of time with us and answered our questions and concerns, and did not rush.

February 04, 2013

Dr. Akerley and his staff are always kind and professional!

November 20, 2012

Doctor Akerly is one of the most considerate and caring doctors i've meet. He always gave me options about my care and let me make the decision. I felt like he trusted my judgement and new what i was talking about. I would recomend him highly, he is the best.

October 31, 2012

We could have had more explanations on medications, but it was all overwhelming and new to me.

October 29, 2012

Huntsman is the BEST in Utah for cancer. And after having to receive treatment myself, I agree that its the very best place to go for cancer treatments

September 25, 2012

Dr. Akerly is an amazing doctor, very caring and he explains things very well! The whole staff is very friendly and makes us feel like they care.

September 17, 2012

I have the utmost confidence in Dr.Akereky and his staff. I have always been treate with respect.

September 10, 2012

Dr. Ackerley and his associates are wonderful. He is kind, thorough and thoughtful. He has always made us feel like he has all the time in the world to answer our questions and doesn't rush us out of the room.

August 20, 2012

My experience with the Dr Ackerley and his staff could not have been better. I have always felt very confident in the care and treatment I have received

June 20, 2012

You can't get better than perfect.

June 11, 2012

Everything is well explained which helps me and my family understand the treatment.

June 05, 2012

I trust Dr. Ackerly and his staff. I fell like I am in the best hands.

April 12, 2012

We came to Huntsman because of your reputation....you are all the best.

April 06, 2012

Dr. Akerley, and his staff, are wonderful about providing information, and even chatting with us about things other than cancer. They are truly part of our family. Although I do not necessarily wish to be a cancer patient, I have thoroughly enjoyed getting to know each and every one of these people. There are so many, but I will name just a few: Dr. Akerly, Terry VanDuren, Jon Nelson, Kelsey, the two young ladies at the front desk, Amanda, Brigitte, ALL of the medical assistants, ALL of the infusion nurses and their assistants, and anyone I know I have missed. My only problem was with the outpatient pharmacy.

April 06, 2012

We are very pleased with the care and concern given by the doctor and the entire staff. We are very pleased and trust our confidence and trust with Dr. Ackerly could not be better.

March 23, 2012

Dr. Akerley always gives the time I feel I need. I don't feel like he is trying to rush through our visit. We are receiving the very best care we could possibly get for my situation.

March 21, 2012

I couldn't think of any way my care and concerns have been addressed any better.

February 21, 2012

The staff taking the time to fully explain each detail/issue and never acting as if the patient nor his family member is asking a stupid question is a wonderful aspect of the treatment experience.

February 17, 2012

I am very pleased with Dr. Akerley and his care. He has always taken the time to talk with me and answer any concerns I have. I am very comfortable with Dr. Akerley and would recommend anyone to him.

February 15, 2012

I was very pleased that Dr. Akerley spent the right amount of time with me even though he was already behind schedule. I appreciate the fact that he needed to take care of another patient. I appreciate it even more when that patient is me. Since I had already waited so long, I am glad he didn't just rush through my appointment so he could get back on schedule. Thanks!!

February 10, 2012

Dr. Ackerley is superb .

February 03, 2012

I have been treated with great respect for 3 years of cancer. I do reccommend it all the time. No place is perfect, not are we patients....... But you are darn close.

February 01, 2012

Excellent

January 27, 2012

Am very impressed with Dr .Ackerley and feel he takes a sincere interest in my care.

January 25, 2012

Dr. Akerley and Julie Smit are wonderful! I've been their patient for several years.

Academic Profile

Research Interests

  • Lung Cancer
  • Clinical Trials
  • Melanoma and Cutaneous Oncology

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor
Academic Divisions Oncology
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)
National Board of Medical Examiners
Cancer Center Programs Experimental Therapeutics

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 585-3453 Huntsman Cancer Institute
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

Wallace Akerley, MD

Senior Director of Community Oncology Research,

Huntsman Cancer Institute

Professor, Department of Medicine, Division of Medical Oncology

Wallace Akerley, MD, is a professor in the Department of Medicine, Division of Medical Oncology at the University of Utah School of Medicine, Senior Director of Community Oncology Research at Huntsman Cancer Institute (HCI), co-director of the Thoracic Cancer Program at HCI, and member of the Experimental Therapeutics Program.

Improvements in cancer treatment evolve from laboratory discoveries, animal studies, and controlled clinical trials. This process is most effective when basic scientists and clinicians work side by side. Huntsman Cancer Institute offers a unique opportunity for basic scientists and clinicians to collaborate in solving problems related to cancer patients. Clinical trials offer promising new treatments to qualifying patients and are a critical step in developing improved cancer treatments.

In addition to his leadership responsibilities, Akerley treats patients with many types of cancer, focusing on lung cancer and melanoma. He participates on the lung cancer committees of two national organizations for cancer treatment: Southwest Oncology Group (SWOG) and National Comprehensive Cancer Network (NCCN). Akerley joined Huntsman Cancer Institute in 2002. Previously, he was director of medical oncology and associate director of the Boston University Cancer Center. He received his medical degree at Brown University in Rhode Island, completed his residency at the University of Southern California (USC), and served additional fellowships at USC/Norris Comprehensive Cancer Center and the Norris Cotton Cancer Center at Dartmouth College in New Hampshire.

Education

Education History

Type School Degree
Fellowship Dartmouth Hitchcock Medical Ctr.
Hematology/Oncology
Fellow
Fellowship University of Southern California
Oncology
Fellow
Residency University of Southern California
Internal Medicine
Resident
Internship University of Southern California
Internal Medicine
Intern
Professional Medical Brown University
Medicine
M.D.
Undergraduate Boston University
Engineering
B.S.

Publications

Selected Provider Publications

Journal Article

  1. Oliver TG, Patel J, Akerley W (2015). Squamous Non-small Cell Lung Cancer as a Distinct Clinical Entity. Am J Clin Oncol, 38(2), 220-6.
  2. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2014). Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw, 12(12), 1738-61.
  3. Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN (2014). Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer, 24(9), 1583-9.
  4. Nelson RE, Stenehjem D, Akerley W (2013). A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. Lung Cancer, 82(3), 461-8.
  5. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M (2013). Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw, 11(6), 645-53; quiz 653.
  6. Akerley WL, Nelson RE, Cowie RH, Spinella DG, Hornberger J (2013). The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer. Curr Med Res Opin, 29(5), 517-25.
  7. Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M (2013). Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 11(5), 562-76.
  8. Akerley W, Boucher K, Rich N, Egbert L, Harker G, Bylund J, Van Duren T, Reddy C (2013). A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer, 79(3), 307-11.
  9. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW Jr, Merritt RE, Moran CA, Niell HB, OMalley J, Patel JD, Ready N, Rudin CM, Williams CC Jr, Gregory K, Hughes M (2013). Small cell lung cancer. J Natl Compr Canc Netw, 11(1), 78-98.
  10. Grossmann KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, De Groot JF, Aiken RD, Olson JJ, Evans BA, Jensen RL (2012). Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. J Neurooncol, 110(2), 257-64.
  11. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW Jr, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM (2012). Non-small cell lung cancer. J Natl Compr Canc Netw, 10(10), 1236-71.
  12. Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL 3rd, Othus M, Sosman JA, Kirkwood JM, Sondak VK (2012). Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res, 18(4), 1129-37.
  13. Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC (2012). Malignant pleural mesothelioma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw, 10(1), 26-41.
  14. Poruk KE, Firpo MA, Boucher KM, Akerley WL, Neumayer LA, Sklow B, Scaife CL, Mulvihill SL (01/01/2012). Assessment of Serum Platelet Factor 4 as a Predictive Marker for VTE and as a Prognostic Biomarker in Pancreatic, Colorectal, Breast, and Lung Cancer. J Surg Res, 172(2), 242-243.
  15. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, OMalley J, Patel JD, Ready N, Rudin CM, Williams CC Jr (2011). Small cell lung cancer. J Natl Compr Canc Netw, 9(10), 1086-113.
  16. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, Ramlau R, Arthur S, Gorbachevsky I, Schwartz B, Schiller JH (2011). Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol, 29(24), 3307-15.
  17. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, ODay SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group, Akerley WL (2011 June 30). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine, 2011 Jun(364(26):), 2507-16.
  18. Akerley W, Edwards S, Wilson R, Van Duren T, Akerley D, Tranter S, Sharry S (2011 June). Awareness of Radon - Associated Health Risks in Utah. Utah's Health: An Annual Review, 16(2011), 58-60.
  19. Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R (2010). Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther, 9(12), 3410-9.
  20. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC (2010). Thymic malignancies. J Natl Compr Canc Netw, 8(11), 1302-15.
  21. Hodi FS, ODay SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363(8), 711-23.
  22. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC (2010). Non-small cell lung cancer. J Natl Compr Canc Netw, 8(7), 740-801.
  23. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W (2009). Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol, 27(31), 5255-61.
  24. Stinchcombe TE, Hodgson L, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Niell HB, Atkins JN, Akerley W, Green MR, Vokes EE (2009). Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol, 4(9), 1117-25.
  25. Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters T (2009). A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. J Thorac Oncol, 4(2), 214-9.
  26. Ettinger DS, Akerley W, Bepler G, Chang A, cheney Rt, Chirieac LR, DAmico TA, Demmy TL et al (2008).

    Non-small cell lung cancer

    . JNCCN, 6(3), 228-269.
  27. Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, fossella F, Grecula JC et al (2008).

    Small cell lung cancer

    . JNCCN, 6(3), 294-314.
  28. Ettinger DS, Akerley W, Bepler G, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Feigenberg SJ, Figlin RA, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Patel JD, Robert F, Sugarbaker DJ, Wood DE (2008). Non-small cell lung cancer. J Natl Compr Canc Netw, 6(3), 228-69.
  29. Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC Jr (2008). Small cell lung cancer. J Natl Compr Canc Netw, 6(3), 294-314.
  30. Akerley W, McCoy J, Hesketh PJ, Goodwin JW, Bearden JD, Atkins JN, Chansky K, Crowley JJ, Gandara DR (2007). Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. J Thorac Oncol, 2(6), 526-30.
  31. Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR (2007). Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol, 25(13), 1698-704.
  32. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH (2006). Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol, 24(31), 5025-33.
  33. Akerley W, Safran H, Zaner K, Ready N, Mega T, Kennedy T (2006). Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. Cancer, 107(5), 1050-4.
  34. Kim DW, Shyr Y, Chen H, Akerley W, Johnson DH, Choy H (2005). Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 63(4), 1029-36.
  35. Kim DW, Shyr Y, Shaktour B, Akerley W, Johnson DH, Choy H (2005). Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer, 50(2), 235-45.
  36. Akerley W, Herndon JE Jr, Lyss AP, Choy H, Turrisi A, Graziano S, Williams T, Zhang C, Vokes EE, Green MR (2005). Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. Clin Lung Cancer, 7(1), 47-53.
  37. Socinski MA, Zhang C, Herndon JE 2nd, Dillman RO, Clamon G, Vokes E, Akerley W, Crawford J, Perry MC, Seagren SL, Green MR (2004). Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol, 15(7), 1033-41.
  38. Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR (2003). Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer, 97(10), 2480-6.
  39. Akerley W, Herndon J, Green M, et al (2003). Dose-Dense Weekly Paclitaxel and Pharmacologic Evaluation for Patients with Stage IIIB-IV Non-Small Cell Lung Cancer: A Phase II Trial of Cancer and Leukemia Group B (CALGB 9731/9765). Cancer, 97, 2480-6.
  40. Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L (2002). A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer, 94(6), 1654-60.
  41. Blackstock AW, Herndon JE 2nd, Paskett ED, Perry MC, Graziano SL, Muscato JJ, Kosty MP, Akerley WL, Holland J, Fleishman S, Green MR (2002). Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst, 94(4), 284-90.
  42. Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L (2002). A Multiinstitutional, Concurrent Chemoradiation Trial of Strontium-89, Estramustine, and Vinblastine for Hormone Refractory Prostate Carcinoma Involving Bone. Cancer, 94(6), 1654-1660.
  43. Akerley W, Rathore R, Ready N, Leone L, Sikov W, Safran H, Kennedy T (2002). A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer, 95(9), 2000-5.
  44. Blackstock A, Herndon J, Paskett E, Perry M, Graziano S, Muscato, Kosty M, Akerley W, Holland J, Fleishman S, Green M (2002). Outcomes Among African-American and Non African-American Patients with Advanced Non-Small Cell Lung Cancer: A Report from the CALGB. J Natl Cancer Inst, 94(4), 284-90.
  45. Makarovskiy A, Siryaporn E, Hixon D, Akerley W (2002). Survival of Docetaxel-resistant Prostate Cancer Cells Depends on Phenotype Alterations and Continuity of Drug Exposure. Cell Mol Life Sci, 59, 1198-1211.
  46. Akerley W (2001). Recent developments in weekly paclitaxel therapy in lung cancer. Curr Oncol Rep, 3(2), 165-9.
  47. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, ODay SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB (2001). Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer, 84(2), 157-63.
  48. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ (2001). Phase II Study of Docetaxel, Estramustine, and Low-dose Hydrocortisone in Men with Hormone-refractory Prostate Cancer: a final report of CALGB 9780. J Clin Oncol, 19(9), 2509-16.
  49. Akerley W (2001). Recent Development in Weekly Paclitaxel Therapy of Lung Cancer. Current Oncology Reports, 3(2), 165-169.
  50. Wanebo H, Chougule P, Ready N, Safran H, Akerley W, Koness R, McRae R, Nigri P, Leone L, Kennedy T, Webber B (2001). Surgical Resection is Necessary to Maximize Tumor Control In Function Preserving, Aggressive Chemoradiation Protocols for Advanced Squamous Cancer of the Head and Neck (Stage III and IV). Ann Surg Oncol, 8, 644-50.
  51. Gurevich I, Akerley W (2001). Treatment of the Jaundiced Patient with Breast Carcinoma. Cancer, 91(4), 660-663.
  52. King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M, Safran H (2000). p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer, 89(4), 769-73.
  53. Akerley W 3rd (2000). Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule. Chest, 117(4 Suppl 1), 152S-155S.
  54. Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H (2000). Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol, 174(1), 57-9.
  55. King T, Akerley W, Fan A, Walsh K, Mangray S, Chen M, Safran H (2000). P53 Mutations Do Not Predict Response to Paclitaxel for Metastatic Non-Small Cell Lung Cancer. Cancer, 89(4), 769-73.
  56. Akerley W (2000). Paclitaxel in Advanced Non-small Cell Lung Cancer: An Alternative High-dose Weekly Schedule. Chest, 117:4 (suppl 1), 152-5.
  57. Dupuy D, Zagoria R, Akerley W, Mayo-Smith W, Kavanagh P, Safran H (2000). Percutaneous Radiofrequency Ablation of Malignancies in the Lung. Am J Roentgenol Radium Ther Nucl Med, 174(1), 57-9.
  58. Akerley W (2000). Secondary Leukemia: Twice is a Coincidence? Cancer, 88(3), 497-9.
  59. Chougule PB, Akhtar MS, Akerley W, Ready N, Safran H, McRae R, Nigri P, Bellino J, Koness J, Radie-Keane K, Wanebo H (1999). Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study. Semin Radiat Oncol, 9(2 Suppl 1), 58-63.
  60. Wanebo HJ, Chougule P, Ready N, Koness RJ, Akerley W, McRae R, Nigri P, Leone L, Webber B, Safran H (1999). Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). Semin Radiat Oncol, 9(2 Suppl 1), 77-84.
  61. Akerley W, Choy H (1999). Single-agent paclitaxel and radiation for non-small cell lung cancer. Semin Radiat Oncol, 9(2 Suppl 1), 85-9.
  62. Chougule P, Akhtar M, Akerley W, Ready N, Safran H, McRae R, Nigri P, Bellino J, Koness R, Radie-Kane K, and Wanebo H (1999). Chemoradiotherapy for Advanced Inoperable Head and Neck Cancer: A Phase II Study. Semin Radiat Oncol, 9(2) suppl 1, 58-63.
  63. Glantz M, Kim L, Choy H, Akerley W (1999). Concurrent Chemotherapy and Radiotherapy in Patients with Brain Tumors. Oncology, 13(10) suppl 5, 78-82.
  64. Wanebo H, Chougule P, Ready N, Koness R, Akerley W, McRae R, Nigri P, Leone L, Webber B, Safran H (1999). Preoperative Paclitaxel, Carboplatin and Radiation Therapy in Advanced Head and Neck Cancer. Semin Radiat Oncol, 9(2) suppl 1, 77-84.
  65. Akerley W and Choy H (1999). Single Agent Paclitaxel and Radiation for Non-Small Cell Lung Cancer. Semin Radiat Oncol, 9(2) suppl 1, 85-89.
  66. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T (1998). Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol, 16(10), 3316-22.
  67. Choy H, Safran H, Akerley W, Graziano SL, Bogart JA, Cole BF (1998). Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res, 4(8), 1931-6.
  68. Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin MJ (1998). High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol, 16(4), 1561-7.
  69. Recht LD, Glantz MJ, Meitner P, Glantz L, Akerley W, Wahlberg L, Saris S, Cole BF (1998). Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). J Neurooncol, 36(3), 201-8.
  70. Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone L (1998). Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol, 16(1), 153-8.
  71. Clamon G, Herndon J, Akerley W, Green M (1998). Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. Lung Cancer, 19(1), 25-9.
  72. Chougule P, Wanebo H, Akerley W, McRae R, Nigri P, Leone L, Safran H, Ready N, Koness RJ, Radie-Keane K, Cole B (1997). Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results. Semin Oncol, 24(6 Suppl 19), S19-57-S19-61.
  73. Wanebo HJ, Chougule P, Akerley WL 3rd, Koness RJ, McRae R, Nigri P, Leone L, Ready N, Safran H, Webber B, Cole B (1997). Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer. Am J Surg, 174(5), 518-22.
  74. Akerley W, Sikov WM, Cummings F, Safran H, Strenger R, Marchant D (1997). Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. Semin Oncol, 24(5 Suppl 17), S17-87-S17-90.
  75. Akerley W, Choy H, Safran H, Sikov W, Rege V, Sambandam S, Wittels E (1997). Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin Oncol, 24(4 Suppl 12), S12-10-S12-13.
  76. Safran H, King TP, Choy H, Hesketh PJ, Wolf B, Altenhein E, Sikov W, Rosmarin A, Akerley W, Radie-Keane K, Cicchetti G, Lopez F, Bland K, Wanebo HJ (1997). Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. J Clin Oncol, 15(3), 901-7.
  77. Makarovskiy A, Ackerley W, Wojcik W, Halpert G, Stein B, Carreiro M, Hixson D (1997). Application of Immunomagnetic Beads in Combination with RT-PCR for the Detection of Circulating Prostate Cancer Cells. J Clin Lab Anal, 11, 346-50.
  78. Choy H, Akerley W, Safran H, Graziano S (1997). Concurrent Weekly Paclitaxel and Radiation Therapy for Locally Advanced NSCLC. Lung Cancer, 18(S2), 152.
  79. Choy H, King T, Akerley W, Safran H (1997). Paclitaxel and Concurrent Radiation for Lung, Pancreatic and Gastric Carcinomas: Significance of p53 Gene Mutations for Treatment Response. Semin Radiat Oncol, 7(3), s77-81.
  80. Choy H, Akerley W, Devore R (1997). Paclitaxel in Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. Advances in Oncology, 13(4), 17-24.
  81. Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L (1997). Phase I Trial of Outpatient Weekly Paclitaxel and Concurrent Radiation Therapy for Advanced Non-Small Cell Lung Cancer. Classic Papers and Current Comments, 2(1), 167-71.
  82. Akerley W (1996). Phase I/II trial of weekly paclitaxel in patients with advanced lung cancer. Semin Oncol, 23(6 Suppl 16), 55-8.
  83. Choy H, Akerley W, Safran H, Graziano S, Chung C (1996). Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. Semin Oncol, 23(6 Suppl 16), 117-9.
  84. Glantz MJ, Choy H, Akerley W, Kearns CM, Egorin MJ, Rhodes CH, Cole BF (1996). Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response. Semin Oncol, 23(6 Suppl 16), 128-35.
  85. Akerley W 3rd, Glantz M, Choy H (1996). Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer. Semin Oncol, 23(5 Suppl 12), 14-8.
  86. Choy H, Akerley W, Glantz M, Safran H, Graziano S, Chung C (1996). Concurrent Paclitaxel and Radiation Therapy for Solid Tumors. Cancer Control, 3(4), 310-318.
  87. Glantz MJ, Cole BF, Friedberg MH, Lathi E, Choy H, Furie K, Akerley W, Wahlberg L, Lekos A, Louis S (1996). A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology, 46(4), 985-91.
  88. Clark J, Sikov W, Cummings F, Browne M, Akerley W, Wanebo H, Weitberg A, Kennedy T, Cole B, Bigley J, Beitz J, Darnowski J (1996). Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol, 122(9), 554-8.
  89. Akerley W, Glantz M, Choy H (1996). Phase I Study of Weekly Outpatient Paclitaxel in Advanced and Metastatic Non-small Cell Lung Cancer. Semin Oncol, 23(5), Suppl 12, 14-18.
  90. Glantz M, Choy H, Akerley W, Kearns C, Egorin M, Rhodes H, Cole B (1996). Weekly Paclitaxel With and Without Concurrent Radiation Therapy: Toxicity, Pharmacokinetics and Response. Semin Oncol, 23(6) Suppl 16, 128-135.
  91. Glantz MJ, Choy H, Kearns CM, Akerley W, Egorin MJ (1995). Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions. Semin Oncol, 22(5 Suppl 12), 26-32.
  92. Glantz MJ, Hall WA, Cole BF, Chozick BS, Shannon CM, Wahlberg L, Akerley W, Marin L, Choy H (1995). Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer, 75(12), 2919-31.
  93. Akerley W, Choy H (1995). Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer. Lung Cancer, 12 Suppl 2, S107-15.
  94. Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L (1994). Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol, 12(12), 2682-6.
  95. Miller ME, Dores GM, Thorpe SL, Akerley WL (1994). Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thromb Res, 74(6), 577-94.
  96. Akerley WL 3rd, Moritz TE, Ryan LS, Henderson WG, Zacharski LR (1993). Racial comparison of outcomes of male Department of Veterans Affairs patients with lung and colon cancer. Arch Intern Med, 153(14), 1681-8.
  97. Posner M, Martin A, Slapak CA, Clark JW, Cummings FJ, Robert NJ, Sikov W, Akerley W (1992). A phase II trial of continuous infusion cisplatin and 5-fluorouracil with oral calcium leucovorin in colorectal carcinoma. Am J Clin Oncol, 15(3), 239-41.
  98. Akerley WL 3rd, Guyre PM, Davis BH (1991). Neutrophil activation through high-affinity Fc gamma receptor using a monomeric antibody with unique properties. Blood, 77(3), 607-15.
  99. Grunberg SM, Ehler E, McDermed JE, Akerley WL (1988). Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin. J Natl Cancer Inst, 80(11), 864-8.
  100. Grunberg SM, Akerley WL, Krailo MD, Johnson KB, Baker CR, Cariffe PA (1986). Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. Cancer Invest, 4(5), 379-85.

Clinical Trials

Video & News

In The News

The Scope Health Sciences Radio

Video